PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicine
Elisa Baldelli(Abterra Biosciences (United States)), Mariaelena Pierobon(George Mason University)
Cited by 14
Related Papers
Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i> Mutant Pancreatic Cancer
|Cancer Research|2022|160
Molecular Analysis of HER2 Signaling in Human Breast Cancer by Functional Protein Pathway Activation Mapping
|Clinical Cancer Research|2012|124
Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers
|Cell Reports|2020|108
P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia
|Nature Cancer|2022|42
Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of HRAS Mutant Head and Neck Squamous Cell Carcinoma
|Molecular Cancer Therapeutics|2022|18